Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00262-020-02725-2 http://scihub22266oqcxt.onion/10.1007/s00262-020-02725-2 33033851!7543968!33033851     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Immunol+Immunother 2021 ; 70 (4): 1127-1142 Nephropedia Template TP {{tp|p=33033851|t=2021. Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm |pdf=|usr=}}{{33033851}} gab.com Text Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm JO: Cancer Immunol Immunother http://www.kidney.de/pget.php?&tw=1&pmid=33033851 #FOAvip Cytokine storm can result from cancer immunotherapy or certain infections, including COVID-19. Though short-term immune-related adverse events are routinely described, longer-term immune consequences and sequential immune monitoring are not as well defined. In 2006, six healthy volunteers received TGN1412, a CD28 superagonist antibody, in a first-in-man clinical trial and suffered from cytokine storm. After the initial cytokine release, antibody effect-specific immune monitoring started on Day + 10 and consisted mainly of evaluation of dendritic cell and T-cell subsets and 15 serum cytokines at 21 time-points over 2 years. All patients developed problems with concentration and memory; three patients were diagnosed with mild-to-moderate depression. Mild neutropenia and autoantibody production was observed intermittently. One patient suffered from peripheral dry gangrene, required amputations, and had persistent Raynaud's phenomenon. Gastrointestinal irritability was noted in three patients and coincided with elevated gammadeltaT-cells. One had pruritus associated with elevated IgE levels, also found in three other asymptomatic patients. Dendritic cells, initially undetectable, rose to normal within a month. Naive CD8(+) T-cells were maintained at high levels, whereas naive CD4(+) and memory CD4(+) and CD8(+) T-cells started high but declined over 2 years. T-regulatory cells cycled circannually and were normal in number. Cytokine dysregulation was especially noted in one patient with systemic symptoms. Over a 2-year follow-up, cognitive deficits were observed in all patients following TGN1412 infusion. Some also had signs or symptoms of psychological, mucosal or immune dysregulation. These observations may discern immunopathology, treatment targets, and long-term monitoring strategies for other patients undergoing immunotherapy or with cytokine storm. Twit Text FOAVip Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm ????Cancer Immunol Immunother http://www.kidney.de/pget.php?&tw=1&pmid=33033851 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33033851 #FOAvip English Wikipedia <ref>{{Cite pmid|33033851}}</ref> Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm #MMPMID33033851 Panoskaltsis N; McCarthy NE; Stagg AJ; Mummery CJ; Husni M; Arebi N; Greenstein D; Price CL; Al-Hassi HO; Koutinas M; Mantalaris A; Knight SC Cancer Immunol Immunother 2021[Apr]; 70 (4): 1127-1142 PMID33033851show ga Cytokine storm can result from cancer immunotherapy or certain infections, including COVID-19. Though short-term immune-related adverse events are routinely described, longer-term immune consequences and sequential immune monitoring are not as well defined. In 2006, six healthy volunteers received TGN1412, a CD28 superagonist antibody, in a first-in-man clinical trial and suffered from cytokine storm. After the initial cytokine release, antibody effect-specific immune monitoring started on Day + 10 and consisted mainly of evaluation of dendritic cell and T-cell subsets and 15 serum cytokines at 21 time-points over 2 years. All patients developed problems with concentration and memory; three patients were diagnosed with mild-to-moderate depression. Mild neutropenia and autoantibody production was observed intermittently. One patient suffered from peripheral dry gangrene, required amputations, and had persistent Raynaud's phenomenon. Gastrointestinal irritability was noted in three patients and coincided with elevated gammadeltaT-cells. One had pruritus associated with elevated IgE levels, also found in three other asymptomatic patients. Dendritic cells, initially undetectable, rose to normal within a month. Naive CD8(+) T-cells were maintained at high levels, whereas naive CD4(+) and memory CD4(+) and CD8(+) T-cells started high but declined over 2 years. T-regulatory cells cycled circannually and were normal in number. Cytokine dysregulation was especially noted in one patient with systemic symptoms. Over a 2-year follow-up, cognitive deficits were observed in all patients following TGN1412 infusion. Some also had signs or symptoms of psychological, mucosal or immune dysregulation. These observations may discern immunopathology, treatment targets, and long-term monitoring strategies for other patients undergoing immunotherapy or with cytokine storm. |Adult[MESH] |Antibodies, Monoclonal, Humanized/*adverse effects/pharmacology[MESH] |CD28 Antigens/*agonists[MESH] |COVID-19/*immunology[MESH] |Cognitive Dysfunction/etiology/*immunology[MESH] |Cohort Studies[MESH] |Cytokine Release Syndrome/etiology/*immunology[MESH] |Drug-Related Side Effects and Adverse Reactions/*immunology[MESH] |Follow-Up Studies[MESH] |Humans[MESH] |Immunotherapy/*adverse effects[MESH] |Male[MESH] |SARS-CoV-2/*physiology[MESH] |T-Lymphocytes/*immunology[MESH]Immune reconstitution and clinical recovery following anti-CD28 antibo(epmc).pdf DeepDyve Pubget Overpricing